scholarly journals Cystatin-C as Novel Marker of Neonatal Hyperbilirubinemia, in Al-Najaf City, Iraq

2021 ◽  
Vol 2 (2) ◽  
pp. 64-70
Author(s):  
Sarah Ali Aljazaeri
Keyword(s):  
Cystatin C ◽  
Serum Levels ◽  
Neonatal Hyperbilirubinemia ◽  
Cysteine Protease Inhibitor ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Male And Female ◽  
Healthy Group ◽  
The Family ◽  
Apparently Healthy

Neonatal hyperbilirubinemia results from a readiness for the bilirubin production in neonates and limited their ability to excrete it. The diagnosis of hyperbilirubinemia based on yellow discoloration of the skin and whiteness of eyes, idle in the child's movement and the lack of lactation. The baby seems sick or is difficult to awaken. Serum cystatin-C, is a low molecular protein that belongs to the family of cysteine protease inhibitor, was proposed as an endogenous filtration marker. In this study sixty neonatal patients suffering from hyperbilirubinemia (35 males,25female) were collected from prematurity unit (PU) in Al-Zahra Educational Hospital/Al-Najaf Al-Ashraf during the period from August,2020 to February,2021. A group of 20 randomly (12male, 8female) selected apparently healthy group. After diagnosis of hyperbilirubinemia, the patients were divided into three groups according to age (1-3), (4-7) and (7-9) days.  The result reveals that significant increase (p<0.05) in serum cystatin-C in neonatal hyperbilirubinemia as compared with healthy group. The result of study reveals no significant increase(p<0.05) in serum levels of cystatin-C, while the study shows a significant increase (p<0.05) between male and female in serum levels of bilirubin. 

scholarly journals Improved Prediction of Decreased Creatinine Clearance by Serum Cystatin C: Use in Cancer Patients before and during Chemotherapy

2000 ◽  
Vol 46 (2) ◽  
pp. 193-197 ◽  
Author(s):  
Borut Štabuc ◽  
Levin Vrhovec ◽  
Mirna Štabuc-Šilih ◽  
Tomaž Edvard Cizej
Keyword(s):  
Serum Creatinine ◽  
Creatinine Clearance ◽  
Cancer Patients ◽  
Cystatin C ◽  
Stepwise Regression ◽  
Roc Analysis ◽  
Cysteine Protease Inhibitor ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Turbidimetric Immunoassay

Abstract Background: Serum cystatin C, a cysteine protease inhibitor, has been suggested as a new marker of glomerular filtration rate (GFR). This study explored the possibility of replacing the creatinine clearance (CrCl) estimation of GFR with cystatin C in early detection of renal impairment in cancer patients on chemotherapy. Methods: Serum creatinine and cystatin C concentrations as well as 24-h CrCl were determined simultaneously in 72 cancer patients. Among them, 60 were treated with combined chemotherapy with cisplatin (CDDP). Creatinine was determined enzymatically with a spectrophotometric method. Serum cystatin C was determined by a particle-enhanced turbidimetric immunoassay. Results: Cystatin C and creatinine correlated significantly (P = 0.001) with CrCl. The correlation was significantly better for cystatin C than creatinine (r = 0.84 vs 0.74; P = 0.01). Stepwise regression analysis identified no differences for the correlations between cystatin C and CrCl in patients with or without metastases (r = 0.82 and 0.84, respectively) as well as before treatment and before the fourth cycle of chemotherapy (r = 0.70 and 0.75, respectively). A cystatin C cutoff concentration of 1.33 mg/L had 87% sensitivity and 100% specificity for detecting CrCl &lt;78 mL/min. ROC analysis indicated that cystatin C was superior to serum creatinine for predicting CrCl &lt;78 mL/min (P &lt;0.04). Conclusions: Serum cystatin C is superior to serum creatinine for detection of decreased CrCl and potentially for the estimation of GFR in cancer patients independent of the presence of metastases or chemotherapy.

scholarly journals PENGARUH PEMBERIAN KONTRAS MEDIA NON IONIK LOW OSMOLAR INTRA VENA TERHADAP KADAR CYSTATIN–C SERUM PADA ORYCTALAGUS CUNICULUS

1970 ◽  
Vol 15 (2) ◽  
Author(s):  
Ariyo Sakso Bintoro ◽  
Soetojo Soetojo ◽  
Doddy M Soebadi
Keyword(s):  
Cystatin C ◽  
Sandwich Elisa ◽  
Intervention Group ◽  
Serum Levels ◽  
Control Group ◽  
Test Results ◽  
Elisa Method ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Ionic Contrast

Objective: To measure effects of low osmolar non ionic contrast media on cystatin–C serum levels on different days after administration. Material and Method: Twenty-two oryctalagus cuniculus were divided into two groups of 11 subjects, each subject receiving intravenous injection of low osmolar non ionic contrast or a placebo solution (NaCl 0,9%). Cystatin-C serum levels of each subject were measured before injection, on days 1, 3, 7, and 10. Cystatin–C serum levels were determined with a sandwich ELISA method. Statistical analysis was performed with t–test. Results: Mean cystatin–C serum levels before injection was 0,00337 ± 0,00101 mg/L. Means from days 1, 3, 7, and 10 after injections were 0,00498 ± 0,00153 mg/L; 0,00565 ± 0,00247 mg/L; 0,00468 ± 0,00157, and 0,00339 ± 0,00188 mg/L respectively. Conclusion: Increase in serum cystatin–C levels on days 1, 3, and 7 was significant. On the 10th day no significant escalation was observed. Compared to the control group, there were significant differences in serum cystatin–C increase on days 1 and 3 in the intervention group, but no significant differences 7 and 10 days after injection.

scholarly journals Cystatin C at Admission in the Intensive Care Unit Predicts Mortality among Elderly Patients

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Maria Aparecida Dalboni ◽  
Daniel de Oliveira Beraldo ◽  
Beata Marie Redublo Quinto ◽  
Rosângela Blaya ◽  
Roberto Narciso ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Elderly Patients ◽  
Cystatin C ◽  
Independent Predictor ◽  
Kidney Injury ◽  
Roc Curves ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin

Introduction. Cystatin C has been used in the critical care setting to evaluate renal function. Nevertheless, it has also been found to correlate with mortality, but it is not clear whether this association is due to acute kidney injury (AKI) or to other mechanism. Objective. To evaluate whether serum cystatin C at intensive care unit (ICU) entry predicts AKI and mortality in elderly patients. Materials and Methods. It was a prospective study of ICU elderly patients without AKI at admission. We evaluated 400 patients based on normality for serum cystatin C at ICU entry, of whom 234 (58%) were selected and 45 (19%) developed AKI. Results. We observed that higher serum levels of cystatin C did not predict AKI ( versus  mg/L; ). However, it was an independent predictor of mortality, H.R. = 6.16 (95% CI 1.46–26.00; ), in contrast with AKI, which was not associated with death. In the ROC curves, cystatin C also provided a moderate and significant area (0.67; ) compared to AKI (0.47; ) to detect death. Conclusion. We demonstrated that higher cystatin C levels are an independent predictor of mortality in ICU elderly patients and may be used as a marker of poor prognosis.

scholarly journals Serum Cystatin C, Kidney Injury Molecule-1, Neutrophil Gelatinase-Associated Lipocalin, Klotho and Fibroblast Growth Factor-23 in The Early Prediction of Acute Kidney Injury Associated With Sepsis in a Chinese Emergency Cohort Study

2021 ◽  
Author(s):  
Yuanyuan Pei ◽  
Guangping Zhou ◽  
Pengfei Wang ◽  
Fang'e Shi ◽  
Xiaolu Ma ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Fibroblast Growth Factor 23 ◽  
Kidney Injury ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Kidney Injury Molecule 1 ◽  
Fgf 23

Abstract Background: Acute kidney injury (AKI) was a common and critical complication of sepsis, and is associated with unacceptable morbidity and mortality. Current diagnostic criteria for AKI was insensitive for early detection. Novel biomarkers included cystatin C, KIM-1, NGAL, klotho and FGF-23 which can predict AKI earlier may allow immediate interventions. We aimed to determine the diagnostic performance of these biomarkers for detecting AKI in sepsis patients.Methods: This prospective observational study was conducted from May 2018 and November 2020, enrolling sequential 162 sepsis patients. AKI’s definition was according to 2012 KDIGO criteria and we divided patients into non-AKI (n=102) and AKI (n=60) groups. Serum levels of several AKI biomarkers were detected by ELISA. The relationship between biomarker levels on admission of AKI were analyzed and discrimination performances comparison were performed.Results: AKI incidence was up to 37.0% (60/162) during hospitalization. Compared with non-AKI group, both serum cystatin C, KIM-1, NGAL and FGF-23 were significantly elevated at admission in septic AKI patients. The areas under the receiver operating curves demonstrated that serum cystatin C had modest discriminative powers for predicting AKI after sepsis, and cystatin C combined with serum creatinine in the prediction of septic AKI increased the diagnostic sensitivity prominently.Conclusion: Serum cystatin C, KIM-1, NGAL and FGF-23 levels are both increased in septic AKI patients. Our study provides reliable evidence that cystatin C solely and combined with serum creatinine may accurately and sensitively predict septic AKI when patients on admission.

scholarly journals Cystatin C and Iris: Advances in the Evaluation of Kidney Function in Critically Ill Dog

2021 ◽  
Vol 8 ◽  
Author(s):  
Fabiola de Oliveira Paes-Leme ◽  
Eliana M. Souza ◽  
Paulo Ricardo Oliveira Paes ◽  
Maderleine Geisa Gomes ◽  
Felipe Santos Muniz ◽  
...  
Keyword(s):  
Critically Ill ◽  
Cystatin C ◽  
Urine Output ◽  
Kidney Injury ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Daily Monitoring ◽  
Early Biomarker

Critically ill hospitalized dogs are subject to certain complications, being acute kidney injury (AKI) a common one. Early diagnosis is crucial, and Cystatin C (CysC) is a reliable and early biomarker. The International Society of Renal Interest (IRIS) states that AKI severity can be assessed by mild changes in creatinine serum levels or reduction of urine output that cannot be considered biomarkers of renal injury but failure or insufficiency. Twenty-eight dogs admitted to the Intensive Care Unit under risk factors for the development of AKI were evaluated. Blood samples were collected for determination of sCr and CysC at admission and after 24, 48, and 72 h. Urine output was measured by daily monitoring, measured by collection in a closed system. The results showed the incidence of AKI was 67.9% based on the IRIS criteria and 78.6% based on cystatin C in critically ill patients' dogs. The measurement of serum cystatin C immediately on admission to the ICU was superior in the early identification of patients with AKI when compared to the IRIS classification and serum creatinine in critically ill dogs.

scholarly journals Correlation of Serum Cystatin C with Atherogenic indices in obese individuals

2015 ◽  
Vol 3 (02) ◽  
Author(s):  
K Deepa ◽  
Sudhir . ◽  
Shubha Jayaram ◽  
S Meera ◽  
M H Rahul
Keyword(s):  
Cardiovascular Disease ◽  
Cystatin C ◽  
Risk Index ◽  
Serum Levels ◽  
Atherogenic Index ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Atherogenic Index Of Plasma ◽  
Atherogenic Indices ◽  
Study Population

Introduction: Human obesity is strongly associated with cardiovascular disease. Cystatin C is a naturally occurring protease inhibitor and marker of cardiovascular disease. The atherogenic indices are used as an index for cardiac risk stratification. Objectives: To estimate the serum levels of Cystatin C in individuals with normal BMI, and obese, aged between 20-39 Yrs and to compare the levels of Cystatin C among these individuals and to correlate the levels of serum Cystatin C with atherogenic index of plasma and other indices. Methodology: The study population was taken from healthy volunteers of Mysore city, aged between 20-39 years of either sex. The study population was divided into 2 groups based on BMI. Each group contains sample size of 60. Fasting serum sample was analyzed for Total Cholesterol, TG, LDL-Cholesterol and HDL cholesterol by enzymatic method and serum Cystatin-C by immune-turbidimetric method using auto-analyser. Statistical Analysis: Analysis of Variance [ANOVA] was used to compare the serum levels of Cystatin C in the two groups. To correlate the serum Cystatin C with atherogenic indices for predicting the cardiovascular risk factors, Pearson’s correlation co-efficient was worked out. Results: The mean serum cystatin C levels in normal BMI group are 0.7±0.03 mg/L, and in Obese group 1.15±0.09 mg/(p value less than 0.001).In the study serum Cystatin C showed a positive correlation with serum triglycerides (r=0.7), Atherogenic index of plasma(AIP ) (r=0.80), TCHOL: HDL (Castelli’s Risk Index I) (r=0.71), HDL: LDL(Castelli’s Risk Index II) (r=0.70) respectively and Atherogenic coefficient (AC) {(NonHDLc)/HDLc}( r=0.60) and negative correlation with serum HDL(r=-0.52) Conclusion: Several indices had been derived from lipid profiles to establish an index for predicting the risk of having coronary event. The atherogenic index of plasma was strongly correlated with the Cystatin C, hence AIP can be used as better index for predicting the preclinical cardiovascular disease because of cost effectiveness in estimation of Cystatin C.

Serum concentration of cystatin C is not affected by cellular proliferation in patients with proliferative haematological disorders

2002 ◽  
Vol 39 (3) ◽  
pp. 308-310 ◽  
Author(s):  
OA Mojiminiyi ◽  
R Marouf ◽  
N Abdella ◽  
M Kortom ◽  
R Abdul-Razzak
Keyword(s):  
Cystatin C ◽  
Blood Count ◽  
Cellular Proliferation ◽  
Normal Subjects ◽  
Full Blood Count ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Gault Formula ◽  
Haematological Disorders ◽  
Apparently Healthy

Background Recent reports have shown elevated concentrations of serum cystatin C (CC) in patients with solid tumours. The aim of our study was to investigate whether patients with proliferative haematological disorders have increased serum concentrations of CC compared with normal subjects. Methods Full blood count, serum CC, β2-microglobulin (β2M) and serum creatinine were determined in 27 apparently healthy subjects and 35 patients with proliferative haematological disorders. Creatinine clearance was calculated using the Cockroft-Gault formula. Results CC and β2M showed a significant correlation with each other ( r = 0·96, P < 0·0001). Serum β2M ( P = 0·001) and the serum β2M:CC ratio ( P = 0·001) were significantly higher in the patients with normal renal function than in controls, but serum CC was not significantly different ( P = 0·08). CC did not show a significant correlation with blood count parameters. Discussion Compared with β2M and the β2M:CC ratio, serum CC is not influenced by cell proliferation in haematological disorders.

Serum Cystatin C, Klotho, and Neutrophil Gelatinase-Associated Lipocalin in the Risk Prediction of Acute Kidney Injury after Acute Myocardial Infarction

2020 ◽  
Vol 10 (6) ◽  
pp. 374-381
Author(s):  
Yuanyuan Pei ◽  
Wen Chen ◽  
Xue Mao ◽  
Jihong Zhu
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Kidney Injury ◽  
Serum Levels ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase

<b><i>Background:</i></b> Patients with acute myocardial infarction (AMI) are at high risk for acute kidney injury (AKI). Novel biomarkers that can predict AKI after AMI may facilitate immediate interventions. Recently, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), and klotho have been established as novel AKI biomarkers. However, their effects have not been studied in patients presenting with AMI. In this study, we will measure the serum levels of these three biomarkers to find reliable biomarkers for early diagnosis of AKI in AMI patients. <b><i>Methods:</i></b> This prospective observational cohort study was conducted between May 2016 and November 2017. A total of 285 consecutive patients with AMI were enrolled. The study was approved by the institutional review board of Peking University People’s Hospital (No. 2016PHB 042-01). AKI was defined according to the KDIGO criteria in 2012. At admission, the clinical data of patients was collected and serum levels of several AKI biomarkers, including cystatin C, NGAL, and klotho, were measured by ELISA. The relationship between biomarker levels of AKI were analyzed and their discrimination performances were compared. <b><i>Results:</i></b> AKI incidence was 17.5% (50/285) during hospitalization. Compared to patients without AKI, the AKI group had higher mortality (20.0% vs. 0.4%,<i> p</i> &#x3c; 0.001) and tended to be older, had higher incidence of chronic kidney disease, severe cardiac function, more cardiac complications, larger doses of diuretics, and less use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker and statins. Moreover, AKI patients experienced an increase in serum cystatin C (3,709.2 ± 2,281.5 vs. 1,918.5 ± 1,140.6 ng/mL, <i>p</i> &#x3c; 0.001), NGAL (118.0 ± 70.3 vs. 91.8 ± 52.3 ng/mL, <i>p</i> = 0.003), and klotho (742.2 ± 497.4 vs. 470.3 ± 257.2 pg/mL, <i>p &#x3c;</i>0.001). Furthermore, the areas under the receiver operating curves demonstrated that serum cystatin C levels at admission had modest discriminative powers for predicting AKI after AMI compared with serum creatinine (0.899, 95% CI, 0.855–0.944 vs. 0.734, 95% CI, 0.649–0.819, <i>p &#x3c;</i>0.001). There was no difference between the discrimination performances of serum creatinine, NGAL, and klotho. <b><i>Conclusion:</i></b> Elevated cystatin C levels are associated with AKI in patients with AMI. This study provides reliable evidence that cystatin C levels may be superior to serum creatinine for predicting AKI after AMI at admission.

scholarly journals Elevation of Serum Cystatin C Levels as a Predictor of Cardiovascular Risk in Type 2 Diabetes Mellitus Patients: A Case-control Study

2021 ◽  
Author(s):  
NS Sumantara ◽  
MR Anusuya
Keyword(s):  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Cystatin C ◽  
Serum Levels ◽  
Diabetic Patients ◽  
Serum Cystatin C ◽  
Type 2 Diabetic Patients ◽  
Serum Cystatin ◽  
Type 2 Dm

Introduction: Patients with type 2 Diabetes Mellitus (DM) exhibit atherogenic lipid profile, increasing the risk for atherosclerosis, compared to people without diabetes. Cystatin C, a naturally occurring protease inhibitor has a key role in pathogenesis of atherosclerosis in type 2 DM patients by inhibiting the elastolytic activity of arterial extracellular matrix by cysteine protease cathepsins. Increased concentration of cystatin C in serum reflects a counterbalance of the damaging elastolytic activity which is involved in the pathogenesis of atherosclerosis in type 2 DM patients. Aim: To determine the serum levels of cystatin C and lipid profile in type 2 DM patients with good and poor glycaemic control and to find out the correlation between serum cystatin C with HbA1c levels and cardiovascular risk markers (non-High-Density Lipoprotein Cholesterol (HDLc), Total Cholesterol (TC)/HDLc, Low-Density Liporotein (LDLc)/HDLc). Materials and Methods: The present case-control study included 60 diabetic patients of 35-75 years of age including both the genders. They were divided into Group A (n=30) with HbA1c ≤6.5% and Group B (n=30) with HbA1c >6.5%. Blood samples were collected in fasting state and analysed for Fasting Blood Sugar (FBS), TC, HDLc, LDLc. FBS was analysed by Hexokinase method, HbA1c by turbidimetric inhibition immunoassay and cystatin C by Immunoturbidimetric method. Other parameters like Non-HDLc and cardiovascular risk ratios TC/HDLc and LDLc/HDLc were calculated. Statistical analysis was done by student’s t-test and statistical significance was established at p-value <0.0001. Pearson’s correlation coefficient was used to examine various parameters. Results: In the present study, it was found that diabetic patients with HbA1c >6.5% showed increased levels of serum cystatin C (1.20±0.73 mg/L), TC (182±46.48 mg/dL), LDLc (137±13.86 mg/dL) and low levels of HDLc (34.7±12.43 mg/dL) compared to diabetic patients with HbA1c ≤6.5%. Increase in serum cystatin C levels correlated well with the increased levels of HbA1c (r=0.92), non-HDLc (r=0.87) and cardiovascular risk ratios like TC/HDLc (r=0.95) and LDLc/HDLc (r=0.97). Conclusion: The elevated serum levels of cystatin C levels correlated well with increased HbA1c and lipid profile indicating the dyslipidemia and proatherogenic status in type 2 diabetic patients with poor glycaemic control. Thus, cystatin C can be considered as the predictive marker for cardiovascular disease in type 2 diabetic patients.

509-P: Utility of Serum Cystatin C in Early Kidney Dysfunction in Prediabetics

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 509-P
Author(s):  
JULIA I.F. BRANDA ◽  
BIANCA ALMEIDA ◽  
SANDRA R.G. VIVOLO
Keyword(s):  
Cystatin C ◽  
Kidney Dysfunction ◽  
Serum Cystatin C ◽  
Serum Cystatin
Sign in / Sign up

Export Citation Format

Share Document